Cargando…
Platform Comparison for Evaluation of ALK Protein Immunohistochemical Expression, Genomic Copy Number and Hotspot Mutation Status in Neuroblastomas
ALK is an established causative oncogenic driver in neuroblastoma, and is likely to emerge as a routine biomarker in neuroblastoma diagnostics. At present, the optimal strategy for clinical diagnostic evaluation of ALK protein, genomic and hotspot mutation status is not well-studied. We evaluated AL...
Autores principales: | Yan, Benedict, Kuick, Chik Hong, Lim, Malcolm, Venkataraman, Kavita, Tennakoon, Chandana, Loh, Eva, Lian, Derrick, Leong, May Ying, Lakshmanan, Manikandan, Tergaonkar, Vinay, Sung, Wing-Kin, Soh, Shui Yen, Chang, Kenneth T. E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154751/ https://www.ncbi.nlm.nih.gov/pubmed/25188507 http://dx.doi.org/10.1371/journal.pone.0106575 |
Ejemplares similares
-
Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022) -
Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment
por: Javanmardi, Niloufar, et al.
Publicado: (2019) -
Mutations of 1p genes do not consistently abrogate tumor suppressor functions in 1p-intact neuroblastoma
por: Kuick, Chik Hong, et al.
Publicado: (2022) -
XAF1 promotes neuroblastoma tumor suppression and is required for KIF1Bβ-mediated apoptosis
por: Choo, Zhang'e, et al.
Publicado: (2016) -
Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)